Marten Steen

Marten Steen, partner at HealthCap, previously worked with global business development at Merck Serono, focusing on both product and technology licensing. Marten Steen is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a Ph.D. in Clinical Chemistry in 2003. He is the author of 16 scientific papers and published in peer-reviewed journals. He also has a BSc degree in Business Administration from the Lund University School of Economics and Management. In addition to Wilson Therapeutics AB, Marten Steen also serves on the board of BioClin Therapeutics Inc, Ultragenyx Inc, Immune Targeting Systems Ltd, and deputy member of the board of Nordic Nanovector. He previously served on the board of FerroKin Biosciences prior to its acquisition by Shire.